Key result
Quality of life significantly improved over time among survivors of VA ECMO for cardiogenic shock, with MLWHFQ scores decreasing from 51.7 at 3 months to 25.4 at ≥9 months (p-trend < 0.01).
Why the study?
Although VA ECMO is used for acute cardiogenic shock with improving short-term survival, the long-term quality of life of this patient population is not well characterized.
Does survival after veno-arterial extracorporeal membrane oxygenation for cardiogenic shock result in good long-term quality of life?
Observational (n=64)
No
Does survival after veno-arterial extracorporeal membrane oxygenation for cardiogenic shock result in good long-term quality of life?
p-value: p=< 0.01
Adult survivors of VA ECMO for cardiogenic shock demonstrate significant and sustained improvements in quality of life over long-term follow-up.
Supports favorable long-term QoL in VA-ECMO survivors; leaves open confirmation in prospective cohorts.
Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is used for the management of acute cardiogenic shock with improving short term survival. However, the long-term quality of life (QOL) of this patient population is not well characterized. We prospectively evaluated the QOL of adult patients who survived VA ECMO support for cardiogenic shock at our institution between October 2011 and January 2018 with the Minnesota Living with Heart Failure Questionnaire (MLWHFQ). We surveyed survivors at 3, 6, and 9 months after discharge, and annually for up to 5 years thereafter. A total of 64 patients were evaluated: mean age 54 ± 13 years, 73% male. There were 178 total surveys completed. MLWHFQ total scores significantly improved over time and this pattern was sustained (51.7 ± 25.3 at 3 months, vs 37.7 ± 23.6 at 6 months, vs 25.4 ± 21.3 at ⩾9 months ( p < 0.01, p-trend < 0.01)). Most patients supported with VA ECMO for cardiogenic shock who survive to discharge demonstrate excellent quality of life, 6 months since index hospitalization, which is maintained over subsequent years.
No takes yet. Share an insight, caveat, or question.
North et al. (2022) conducted an observational in Cardiogenic shock (n=64). VA ECMO was evaluated on Minnesota Living with Heart Failure Questionnaire (MLWHFQ) total scores (p=< 0.01). Quality of life significantly improved over time among survivors of VA ECMO for cardiogenic shock, with MLWHFQ scores decreasing from 51.7 at 3 months to 25.4 at ≥9 months (p-trend < 0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: